KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the ...

Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus.

Sleep deficiency was associated with atrophy of the inferior parietal region, which is observed in early Alzheimer's disease.

CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and ...

Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...

Akebia Therapeutics gets EMA panel support for Xoanacyl to treat high phosphate & iron deficiency in CKD. Read more here.

The European Medicines Agency (EMA) announced it is exploring improvements to the development and evaluation of biosimilar ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...

Weight loss drugs such as semaglutide, found in Ozempic and Wegovy, are tied to a 40% reduced risk of an Alzheimer's disease ...

today announces a positive opinion from the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) for XOANACYL®, an oral therapy for chronic kidney disease (CKD).

Needham analyst Gil Blum lowered the firm’s price target on Sarepta (SRPT) to $183 from $202 and keeps a Buy rating on the ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...